SecBot SecBot
SECBOTREPLAY Home › Report › SION

SION · Sionna Therapeutics announced completion of patient enrollment in its…

Sionna Therapeutics, Inc. · PRESS-RELEASE filed Apr 27, 2026 at 07:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Apr 27, 2026 at 07:00 ET

Sionna Therapeutics announced completion of patient enrollment in its Phase 2a PreciSION CF trial evaluating SION-719, a first-in-class NBD1 stabilizer, in cystic fibrosis patients on Trikafta. Topline data is expected in summer 2026, marking a key clinical catalyst for the company's novel CFTR-targeting approach.

  • Completed enrollment in Phase 2a PreciSION CF trial for SION-719, a first-in-class NBD1 stabilizer.
  • Trial evaluates SION-719 added to Trikafta in F508del-homozygous CF patients using a crossover design.
  • Primary endpoints include safety, pharmacokinetics, and change in sweat chloride levels (a biomarker of CFTR function).
  • Topline data expected in summer 2026, representing a near-term clinical readout.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access